$0.01
50.00%
Nasdaq, Sep 24, 12:15 pm EDT. Closed.
ISIN
US71678J1007
Symbol
PTPI

Petros Pharmaceuticals Inc Stock price

$0.01
+0.00 19.05% 1M
-0.00 30.56% 6M
-0.00 37.50% YTD
-0.02 80.47% 1Y
-38.75 99.99% 3Y
-487.50 100.00% 5Y
-12,400.00 100.00% 10Y
-178.41 100.00% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
+0.00 25.00%
ISIN
US71678J1007
Symbol
PTPI
Industry

Is Petros Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$210.0k
Enterprise Value
$3.8m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
0.0 | 0.0
EV/Sales
0.7 | 0.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-70.2%
Return on Equity
358.9%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $5.6m
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 9.3%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
25.1%
Employees
18
Rev per Employee
$280.0k

Petros Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Petros Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Petros Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from Petros Pharmaceuticals Inc

Dec '24
+/-
%
5.11 5.11
57% 57%
100%
- Direct Costs 1.21 1.21
61% 61%
24%
3.90 3.90
56% 56%
76%
- Selling and Administrative Expenses 8.75 8.75
44% 44%
171%
- Research and Development Expense 2.62 2.62
34% 34%
51%
-7.46 -7.46
55% 55%
-146%
- Depreciation and Amortization 2.83 2.83
51% 51%
55%
EBIT (Operating Income) EBIT -10 -10
54% 54%
-201%
Net Profit -27 -27
20% 20%
-524%

In millions USD.

Don't miss a Thing! We will send you all news about Petros Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Head office United States
CEO John Shulman
Employees 18
Website www.petrospharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today